CN1130349C - 苯基－烷基－咪唑类型的h3受体配体 - Google Patents

苯基－烷基－咪唑类型的h3受体配体 Download PDF

Info

Publication number
CN1130349C
CN1130349C CN98812981A CN98812981A CN1130349C CN 1130349 C CN1130349 C CN 1130349C CN 98812981 A CN98812981 A CN 98812981A CN 98812981 A CN98812981 A CN 98812981A CN 1130349 C CN1130349 C CN 1130349C
Authority
CN
China
Prior art keywords
compound
compounds
formula
treating
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN98812981A
Other languages
English (en)
Chinese (zh)
Other versions
CN1285822A (zh
Inventor
R·G·阿斯兰尼亚
K·D·麦科米克
M·W·穆塔希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1285822A publication Critical patent/CN1285822A/zh
Application granted granted Critical
Publication of CN1130349C publication Critical patent/CN1130349C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN98812981A 1997-11-07 1998-11-05 苯基－烷基－咪唑类型的h3受体配体 Expired - Fee Related CN1130349C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US96634497A 1997-11-07 1997-11-07
US08/966344 1997-11-07
US08/966,344 1997-11-07
US12971198A 1998-08-05 1998-08-05
US09/129711 1998-08-05
US09/129,711 1998-08-05

Publications (2)

Publication Number Publication Date
CN1285822A CN1285822A (zh) 2001-02-28
CN1130349C true CN1130349C (zh) 2003-12-10

Family

ID=26827847

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98812981A Expired - Fee Related CN1130349C (zh) 1997-11-07 1998-11-05 苯基－烷基－咪唑类型的h3受体配体

Country Status (17)

Country Link
EP (1) EP1028947B8 (enExample)
JP (1) JP2001522835A (enExample)
KR (1) KR20010031724A (enExample)
CN (1) CN1130349C (enExample)
AR (1) AR016672A1 (enExample)
AT (1) ATE219062T1 (enExample)
AU (1) AU1296699A (enExample)
CA (1) CA2308586A1 (enExample)
CO (1) CO5011065A1 (enExample)
DE (1) DE69806042T2 (enExample)
ES (1) ES2174510T3 (enExample)
HU (1) HUP0004292A3 (enExample)
IL (1) IL135729A0 (enExample)
NZ (1) NZ504124A (enExample)
PE (1) PE134399A1 (enExample)
TW (1) TW421645B (enExample)
WO (1) WO1999024405A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
EP1373251A2 (en) 2001-03-13 2004-01-02 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
PL374758A1 (en) * 2002-10-24 2005-10-31 Merck Patent Gmbh Methylene urea derivatives
WO2006076706A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
EP1749523A1 (en) * 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
WO2007035703A1 (en) 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
AU2013307688A1 (en) * 2012-08-29 2015-04-09 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578616A (en) * 1993-11-15 1996-11-26 Schering Corporation Phenyl-alkyl-imidazoles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
PL191073B1 (pl) * 1996-08-16 2006-03-31 Schering Corp Zastosowanie kombinacji antagonistów receptorów histaminowych H1 i H3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578616A (en) * 1993-11-15 1996-11-26 Schering Corporation Phenyl-alkyl-imidazoles

Also Published As

Publication number Publication date
HUP0004292A2 (hu) 2001-11-28
EP1028947B1 (en) 2002-06-12
DE69806042D1 (de) 2002-07-18
CA2308586A1 (en) 1999-05-20
NZ504124A (en) 2002-10-25
KR20010031724A (ko) 2001-04-16
WO1999024405A1 (en) 1999-05-20
CN1285822A (zh) 2001-02-28
ES2174510T3 (es) 2002-11-01
TW421645B (en) 2001-02-11
HK1025968A1 (en) 2000-12-01
JP2001522835A (ja) 2001-11-20
EP1028947B8 (en) 2004-01-28
CO5011065A1 (es) 2001-02-28
ATE219062T1 (de) 2002-06-15
EP1028947A1 (en) 2000-08-23
DE69806042T2 (de) 2003-01-23
AR016672A1 (es) 2001-07-25
HUP0004292A3 (en) 2001-12-28
AU1296699A (en) 1999-05-31
PE134399A1 (es) 2000-01-10
IL135729A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
JP6728208B2 (ja) ベンザゼピンジカルボキサミド化合物
US6211182B1 (en) Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
EP0618905B1 (en) Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
US5990147A (en) H3 receptor ligands of the phenyl-alkyl-imidazoles type
EP1121354B1 (en) N-(imidazolylalkyl)substituted cyclic amines as histamine-h 3 agonists or antagonists
CN103508936A (zh) 用于制备吲哚苄胺化合物的中间体
CN1387526A (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
US6034251A (en) Phenyl-alkyl-imidazoles
JP3026945B2 (ja) ３−アザ及び３−オキサピペリドンタキキニン拮抗薬
CN1130349C (zh) 苯基－烷基－咪唑类型的h3受体配体
EP1028948B1 (en) Phenyl-alkyl-imidazoles as h3 receptor antagonists
IL264141A (en) Heteroaromatic modulators of the retinoid-related orphan receptor gamma
CN1461304A (zh) 作为双组织胺h1和h3促效剂或拮抗剂的取代的咪唑类化合物
CN101547920A (zh) 取代的5-唑-2-基-喹啉化合物的昔奈酸盐
KR20010031839A (ko) 한 개의 질소원자를 함유하는 5, 6 또는 7원헤테로사이클릭 환으로 치환된 이미다조일알킬
CN1681803A (zh) 芳酰基－哌啶衍生物
JP2004509869A (ja) 二重ヒスタミンｈ１およびｈ３アゴニストまたはアンタゴニストとしての、置換されたイミダゾール
US20030207876A1 (en) 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
MXPA00004400A (en) H3 receptor ligands of the phenyl-alkyl-imidazoles type
HK1025968B (en) H3 receptor ligands of the phenyl-alkyl-imidazoles type
MXPA01009094A (en) Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
CN101124216A (zh) 杂环MCHr1拮抗剂及其在治疗中的用途
JP2010533175A (ja) 置換５−オキサゾール−２−イル−キノリン化合物の塩酸塩およびその生成方法
HK1093338B (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
HK1093338A1 (zh) 具有5-ht4受体激动活性的苯并咪唑酮化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee